Radiopharmacies Market

According to market projections provided by Future Market Insights, there has been significant change in the market dynamics of radiopharmacies with the increasing rate of usage of Positron Emission Tomography (PET) scans, as well as theranostics, regulator expectation of better handling of cGMP requirements, and hospitals turning more towards services that can provide timely availability. There has been an increase in diversification beyond 18F-FDG for Prostate-Specific Membrane Antigen (PSMA) and neuro use, which has caused a shift towards scalable, yet quality-assured, distribution systems.